Literature DB >> 19767623

Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective.

Ann L N Chapman1, Simon Dixon, Dawn Andrews, Patrick J Lillie, Rohit Bazaz, Julie D Patchett.   

Abstract

OBJECTIVES: Outpatient parenteral antibiotic therapy (OPAT) is an effective treatment strategy for a wide variety of infections as long as clinical risk is minimized by conforming to practice guidelines. However, its cost-effectiveness has not been established in the setting of the UK National Health Service. We examined the clinical efficacy and cost-effectiveness of an OPAT service based in a large UK teaching hospital, predominantly using the outpatient 'infusion centre' and patient/carer administration models of service delivery. PATIENTS AND METHODS: Data on clinical activity and outcomes were collected prospectively on 334 episodes of treatment administered by the Sheffield OPAT service between January 2006 and January 2008. Cost-effectiveness was calculated by comparing real costs of OPAT with estimated inpatient costs for these patient episodes incorporating two additional sensitivity analyses.
RESULTS: Of the OPAT episodes, 87% resulted in cure or improvement on completion of intravenous therapy. The readmission rate was 6.3%, and patient satisfaction was high. OPAT cost 41% of equivalent inpatient costs for an Infectious Diseases Unit, 47% of equivalent inpatient costs using national average costs and 61% of inpatient costs using minimum inpatient costs for each diagnosis.
CONCLUSIONS: Using this service model, OPAT is safe and clinically effective, with low rates of complications/readmissions and high levels of patient satisfaction. OPAT is cost-effective when compared with equivalent inpatient care in the UK healthcare setting.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19767623     DOI: 10.1093/jac/dkp343

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  54 in total

1.  Economic evaluation of treatment for MRSA complicated skin and soft tissue infections in Glasgow hospitals.

Authors:  R A Seaton; S Johal; J E Coia; N Reid; S Cooper; B L Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-31       Impact factor: 3.267

2.  Cost-effectiveness of outpatient parenteral antibiotic therapy: a simulation modelling approach.

Authors:  A Vargas-Palacios; D M Meads; M Twiddy; C Czoski Murray; C Hulme; E D Mitchell; A Gregson; P Stanley; J Minton
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

3.  Tolerability of cefazolin after immune-mediated hypersensitivity reactions to nafcillin in the outpatient setting.

Authors:  Kimberly G Blumenthal; Ilan Youngster; Erica S Shenoy; Aleena Banerji; Sandra B Nelson
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

4.  Prediction model for 30-day hospital readmissions among patients discharged receiving outpatient parenteral antibiotic therapy.

Authors:  Genève M Allison; Eavan G Muldoon; David M Kent; Jessica K Paulus; Robin Ruthazer; Aretha Ren; David R Snydman
Journal:  Clin Infect Dis       Date:  2013-12-19       Impact factor: 9.079

5.  Hospital costs for patients with lower extremity cellulitis: a retrospective population-based study.

Authors:  Douglas Challener; Jasmine Marcelin; Sue Visscher; Larry Baddour
Journal:  Hosp Pract (1995)       Date:  2017-09-27

6.  Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting.

Authors:  Ilan Youngster; Erica S Shenoy; David C Hooper; Sandra B Nelson
Journal:  Clin Infect Dis       Date:  2014-04-29       Impact factor: 9.079

7.  Comparative outcomes of β-lactam antibiotics in outpatient parenteral antibiotic therapy: treatment success, readmissions and antibiotic switches.

Authors:  Boeun Lee; Idy Tam; Bernard Weigel; Janis L Breeze; Jessica K Paulus; Jason Nelson; Genève M Allison
Journal:  J Antimicrob Chemother       Date:  2015-05-29       Impact factor: 5.790

Review 8.  Outpatient parenteral antimicrobial therapy with ceftriaxone, a review.

Authors:  Christopher J A Duncan; David A Barr; R Andrew Seaton
Journal:  Int J Clin Pharm       Date:  2012-04-17

9.  Setting up an outpatient parenteral antimicrobial therapy (OPAT) unit in Switzerland: review of the first 18 months of activity.

Authors:  C Gardiol; R Voumard; C Cochet; S de Vallière
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-17       Impact factor: 3.267

10.  Outpatient parenteral antimicrobial therapy (OPAT) in the Republic of Ireland: results of a national survey.

Authors:  E G Muldoon; G M Allison; D Gallagher; D R Snydman; C Bergin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-06-01       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.